{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:30:28Z","timestamp":1793457028097,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106275","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:47:29Z","timestamp":1736873249000},"page":"106275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries"],"prefix":"10.1016","volume":"94","author":[{"given":"Berenice Anabel","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C\u00e9lica","family":"Ysrraelit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Constanza","family":"Segamarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cragnolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Galleguillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Javier","family":"Halfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Miguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Parada Marcilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vrech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"D'Eramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Negrotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106275_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104735","article-title":"Safety and effectiveness of cladribine tablets for multiple sclerosis: results from a single-center real-world cohort","volume":"75","author":"Aerts","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106275_bib0004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106275_bib0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106275_bib0010","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","article-title":"Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg\/kg for Relapsing Multiple Sclerosis: an Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies","volume":"38","author":"Giovannoni","year":"2021","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.msard.2025.106275_bib0006","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/13524585211049392","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","volume":"28","author":"Giovannoni","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106275_bib0011","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106275_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with Cladribine Tablets Beyond Year 4: a Position Statement by Southeast European Multiple Sclerosis Centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol. Ther."},{"issue":"16","key":"10.1016\/j.msard.2025.106275_bib0002","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/0113894501272301231124074141","article-title":"The Development of the Combination Drug Leukovir\u00ae Tablets for the Treatment of Multiple Sclerosis: a Comprehensive Review","volume":"24","author":"Kalinichenko","year":"2023","journal-title":"Curr. Drug Targets."},{"issue":"1","key":"10.1016\/j.msard.2025.106275_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106275_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106275_bib0019","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-Agreed Practical Recommendations on the Use of Cladribine","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"issue":"16","key":"10.1016\/j.msard.2025.106275_bib0012","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion","volume":"21","author":"Meuth","year":"2020","journal-title":"Expert. Opin. PharmacOther"},{"issue":"13","key":"10.1016\/j.msard.2025.106275_bib0013","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert. Opin. PharmacOther"},{"issue":"15\u201316","key":"10.1016\/j.msard.2025.106275_bib0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","article-title":"Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety","volume":"172","author":"Moser","year":"2022","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.msard.2025.106275_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106275_bib0018","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: a Real-World, Multicenter, 2-Year Follow-Up Study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."},{"issue":"11","key":"10.1016\/j.msard.2025.106275_bib0020","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1007\/s00415-023-11846-4","article-title":"Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group\u200f Viewpoint","volume":"270","author":"Petrou","year":"2023","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106275_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106275_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106275_bib0017","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","article-title":"Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study","volume":"270","author":"Zanetta","year":"2023","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T14:16:40Z","timestamp":1740665800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"alternative-id":["S2211034825000197"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106275","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106275"}}